cells

ANTI-TIGIT Antibodies –
AB308

AB308

AB308 is a second investigational anti-TIGIT monoclonal antibody that is Fc-enabled. AB308 in combination with zimberelimab is currently being investigated in a Phase 1b study of people with advanced solid and hematologic malignancies.

See all AB308 clinical trials
Learn More arrow
See all AB308 presentations
Learn More arrow